ABSTRACT
Objective To study the effect of Shensongyangxin Capsule on hemodynamics in the patients with chronic heart failure complicating ventricular arrhythmia .Methods A total of 126 patients with chronic heart failure complicating ventricular ar-rhythmia treated in this hospital from August 2013 to January 2016 were selected as the study subjects for conducting the prospec-tive study .The former 63 cases served as the observation group and the latter 63 cases as the control group .The control group were treated with conventional Western medicines .On the basis of the control group ,the observation group was auxiliarily given Shens-ongyangxin Capsule .Both groups were treated for 8 weeks .The curative effects and hemodynamics were compared between the two groups .Results The total effective rate in the control group was 85 .7% ,which was significantly lower than 96 .8% in the treat-ment group (P<0 .05) .The central artery pressure(MAP) was in the normal range before and after treatment in two groups ,the difference between the two groups had no statistical significance (P>0 .05) .The LVDd and LVDs values after treatment in the ob-servation group were significantly higher than those in the control group (P<0 .05) ,and the LVDd and LVDs values after treat-ment in the two groups were significantly higher than those before treatment (P<0 .05) .The QTcd values after treatment in the observation group and control group were significantly lower than those before treatment (P<0 .05) ,the QTcd values after treat-ment in the observation group were significantly lower than those in the control group (P< 0 .05) .Conclusion Shensonyangxin Capsule in the treatment of chronic heart failure complicating ventricular arrhythmia does not lead to the hemodynamic abnormali-ties ,promotes the heart function improvement and plays the antiarrhythmic effect and increases the curative effect .
ABSTRACT
Objective: To evaluate the feasibility, safety and efficacy of transcatheter closure of ventricular septal defect (VSD) in patients with aortic valve prolapse (AVP) and mild aortic regurgitation (AR). Methods: Between January 2008 and July 2014, transcatheter closure of VSD was attempted in 65 patients. Results: The total intermediate closure successful rate in all subjects was 96.9%. During the perioperative period, no death, major bleeding, pericardial tamponade, occluder dislodgement, residual shunt or hemolysis occurred. Two procedures had been forced to suspend due to significant aggregation of device related aortic regurgitation, three cases of transient complete left bundle branch block occurred but did not sustain. At 1-year follow-up, no patients had residual shunts and complications. Furthermore, grade of residual AR were relieved in 61.9% (39/63) cases and degree of AVP were ameliorated in 36.5% (23/63) patients; Conclusions: Transcatheter closure VSD in selected patients with AVP and mild AR is technically feasible and highly effective. Long term safety and efficacy needs to be assessed.
ABSTRACT
Objective To study the feasibility and long-term effects in 173 infants with congenital ventricular septal defect who underwent transcatheter therapy by double-disk ventricular septal defect occluder. Methods We analyzed the clinical data of 173 infants with ventricular septal defect who were performed interventional therapy followed by a follow up study from December 2002 to October 2013. Results The procedure was performed in 173 infants (male = 81 cases and female = 92 cases) aged 11 month-3 years[(2.1±0.7)years]. The weight were 6-15 kg[(10.2±3.6)kg]. The diameter of the defects ranged from 2.5-9.0 mm[(5.1±1.7) mm]. The characteristics of septal were classiifed into four types:the simply perimembranous ventricular septal defects (88 patient,50.8%), the perimembranous ventricular septal defects with pseudoaneurysm (52 patients, 30.0%), the perimembranous ventricular septal defects complicated with aortic valve prolapse (13 patients, 7.5%), and the intracristal ventricular septal defect (20 patients, 11.7%). The diameter of the occluders were between 4-12 mm[(6.3±2.2)mm]. The period of follow-up ranged from 1 month-10 years[(6.2±1.3)years]. The 168 defects were completely occluded in 173 patients(97.1%closure rate) except 5 infants, which 3 patients because the occluder hinder the function of aortic valves and the other occurred complete atrioventricular block(CAVB) when the catheter through defect. One patient occurred CAVB on the third day after the procedure, was reversed by dexamethasone after 4 days. 3 patients with complete left bundle branch block(CLBBB) after the procedure and one went to sustained, but did not observed heart failure in this case during 5 years follow-up. One patient observed sustained CLBBB on the fourth year after the procedure, also did not observed heart failure in this case during 3 years follow-up. 8 patients with trivial residual shun and 4 patients with newly appearance of trivial aortic regurgitation after the procedure, the shun all disappear at one year and the regurgitation did not progress during longest follow-up period at 8.5 years. No other complications, including late-onset CAVB, hematolysis, the occluder displacement and detachment, occurred during 1 month-10 years of follow-up. Conclusions Transcatheter closure of congenital ventricular septal defects is an efifcient method that can be safely used in the majority of infants with ventricular septal defects and have signiifcant long-term effects.
ABSTRACT
Objective To identify the middle-long term outcomes,the incidence of restenosis,and the determining factors of restenosis.Methods Four hundred and sixty five patients with mitral stenosis (MS) underwent percutaneous balloon mitrail valvuloplasty (PBMV) from May 1990 to May 2002. Among the 465 patients,a retrospective study of 344 cases (258 females and 86 males) with complete data was presented in this article. The mean age was (40.2?9.6) years (ranging from 15 to 72 years). They were followed-up after PBMV. The data were analyzed with SAS software. Results Follow-up results of 1-12 years [median (3.6?2.5) years] showed that the one-year event-free survival rate was 100% with 9 cases of restenosis in 344 cases (2.5%),the three-years event-free survival rate was 97% with 39 cases of restenosis in 286 cases (13.6%),the five-years event-free survival rate was 91% with 60 cases of restenosis in 221 cases (27.1%),the eight-year event-free survival rate was 80% with 32 cases of restenosis in 81 cases (39.5%),and the ten-year event-free survival rate was 69% with 20 cases of restenosis in 42 cases (47.6%),and the twelve-year event-free survival rate was 63% with 9 cases of restenosis in 16 cases (56.3%). The event-free survival rate was greater in patients with modified echocardiographic score ≤10. Conclusion PBMV can produce good clinical middle and long-term outcomes in most patients,and those with modified echocardiographic score ≤10,bi-commissural splitting,sinus rhythm,large mitral valve area after PBMV,without poor cardiac function may especially have the best middle and long-term results.
ABSTRACT
Objective To evaluate the safety and efficacy of percutaneous balloon mitral valvuloplasty (PBMV) in patients with rheumatic severe mitral stenosis and thrombus in the left atrial appendage.Methods We selected 11 patients (9 women and 2 men), the average age being 40.6?5.7 years. All cases received warfarin orally every day for more than 12 weeks before underwent PBMV used Inoue single balloon technique, to see whether systemic thromboembolism complication occurred during the operation and one year follow-up term. Results The successful rate of PBMV was 100%. No systemic thromboembolism occurred during and after PBMV. The parameters of hemodynamics, mitral valve area and cardiac function improved markedly.Conclusion PBMV on patients with severe mitral stenosis and thrombus in the left atrial appendage is safe and effective after certain anticoagulation treatment.